CREST-2 Randomized Clinical Trial (C2LOE)


About this study

The purpose of this study is to compare the post-procedure treatment differences in stroke risk between those randomized to revascularization and intensive medical management (IMM) and those randomized to IMM alone.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult men and women (≥ 18 years old) with asymptomatic highgrade carotid stenosis who are current participants or have completed 4 years of follow-up in the CRES T-2 trial.
  • Able to provide written informed consent by self.
  • Fluent in English.

Exclusion Criteria:

  • Individuals < 18 years old.
  • Unable to provide written informed consent.
  • Inability to follow study procedures.

Eligibility last updated 2/11/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Albert Hakaim, M.D.

Open for enrollment

Contact information:

Eldina Stojadinovic

More information


Publications are currently not available

Mayo Clinic Footer